IDiyas

For the Inventor, By the Inventor

Spring House, PA, United States of America

Shalom Goldberg

USPTO Granted Patents = 13 

 

Average Co-Inventor Count = 5.6

ph-index = 3

Forward Citations = 26(Granted Patents)


Location History:

  • Spring House, PA (US) (2019 - 2024)
  • Merion Station, PA (US) (2020 - 2024)

Company Filing History:

goldMedal13 out of 410 
 
Janssen Biotech, Inc.
 patents

Years Active: 2019-2025

Loading Chart...
Loading Chart...
13 patents (USPTO):
1. 12453785 - Macrocyclic chelators and methods of use thereof (2025-10-28),
2. 12240790 - Radiolabeling of polypeptides (2025-03-04),
3. 12227593 - Site-specific conjugation of glycosylated monoclonal antibodies with transglutaminase (2025-02-18),
4. 12084475 - Methods for site specific conjugation of proteins containing glycosylated Fc domains (2024-09-10),
5. 12054534 - Prostate specific membrane antigen binding fibronectin type iii domains (2024-08-06),
6. 11987641 - Anti-PSMA antibodies and uses thereof (2024-05-21),
7. 11702475 - Cysteine engineered fibronectin type III domain binding molecules (2023-07-18),
8. 11576986 - Macrocyclic chelators and methods of use thereof (2023-02-14),
9. 11072663 - Cysteine engineered fibronectin type III domain binding molecules (2021-07-27),
10. 10844122 - Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof (2020-11-24),
11. 10844111 - Prostate specific membrane antigen binding fibronectin type III domains (2020-11-24),
12. 10662235 - Cysteine engineered fibronectin type III domain binding molecules (2020-05-26),
13. 10196446 - Cysteine engineered fibronectin type III domain binding molecules (2019-02-05),

Title: Shalom Goldberg: Innovator in Radiopharmaceuticals

Introduction

Shalom Goldberg is a prominent inventor based in Spring House, PA, known for his significant contributions to the field of radiopharmaceuticals. With a total of 13 patents to his name, he has made remarkable advancements in the development of macrocyclic chelators and radiolabeling techniques.

Latest Patents

Goldberg's latest patents include innovative methods for macrocyclic chelators designed for the chelation of alpha-emitting radiometal ions, such as actinium-225. These patents provide detailed descriptions of radiometal complexes that contain an alpha-emitting radiometal ion bound to the macrocyclic chelator through coordinate bonding. Additionally, he has developed radioimmunoconjugates that incorporate these radiometal complexes, which can be covalently linked to targeting ligands, such as antibodies or antigen-binding fragments. The production of these radioimmunoconjugates utilizes click chemistry reactions, enhancing their efficacy in selectively targeting neoplastic cells for radiotherapy and treating various neoplastic diseases and disorders. Furthermore, Goldberg has improved methods for radiolabeling antibodies using click chemistry, along with pharmaceutical compositions and applications related to the radiolabeled antibodies produced by these methods.

Career Highlights

Shalom Goldberg is currently associated with Janssen Biotech, Inc., where he continues to push the boundaries of innovation in the pharmaceutical industry. His work has not only advanced scientific understanding but has also paved the way for new therapeutic options in cancer treatment.

Collaborations

Goldberg collaborates with notable colleagues, including Steven Jacobs and Karyn O'Neil, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Shalom Goldberg's contributions to the field of radiopharmaceuticals exemplify the impact of innovative thinking in medicine. His patents and ongoing work at Janssen Biotech, Inc. highlight the importance of advancements in targeted therapies for neoplastic diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…